The safety and efficacy of endoscopic ultrasound-guided ablation therapy for solid pancreatic tumors: a systematic review

Recently, endoscopic ultrasound (EUS)-guided ablation therapy, as a minimally invasive technique, has shown its potential to substitute surgery in treating solid pancreatic tumors, such as small potential malignant pancreatic tumors, small insulinomas and locally advanced pancreatic ductal adenocarcinoma (LAPDAC). Therefore, we conducted this systematic review to assess the safety and efficacy of EUS-guided ablation therapy for solid pancreatic tumors. We conducted a comprehensive search of PubMed, Embase, Cochrane library and Web of Science databases from inception to February 2020. The endpoints were clinical success and complications rates. The pooled event rate was calculated using Comprehensive Meta Analysis software. Fourteen studies with a total of 158 patients were included in our final analysis. The major types of solid pancreatic tumors were nonfunction pancreatic neuroendocrine tumors (<i>n</i> = 78, 49.4%), LAPDAC (<i>n</i> = 48, 30.4%) and insulinomas (<i>n</i> = 26, 16.5%). Overall, the pooled clinical success rate was 85.9% (95% confidence interval (CI): 75.4–92.4%, <i>I</i>² = 25.18%), pooled complications rate was 29.1% (95% CI: 18.6–42.3%, <i>I</i>² = 50.40%). Subgroup analysis was performed based on ablation methods, which showed clinical success rate for radiofrequency ablation (RFA) was 83.5% (95% CI: 67.9–92.4%), and 87.9% (95% CI: 66.2–96.4%) for ethanol ablation (EA). In terms of complications rate, it was 32.2% (95% CI: 19.4–48.4%) for RFA, and 21.2% (95% CI: 6.8–49.9%) for EA. EUS-guided ablation therapy is a promising alternative treatment for solid pancreatic tumors, especially for p-NETs and insulinomas &lt; 2 cm, with rarely severe complications. Further prospective studies with long-term follow-up are warranted in future.